Fresenius Petitions FDA to Deny Second Indication for Keryx’s Chronic Kidney Disease Drug

Drug Industry Daily
A A
Citing safety concerns, Fresenius asked the FDA to withhold approval for an additional indication for Keryx’s sNDA for Auryxia.

To View This Article:

Login

Subscribe To Drug Industry Daily